Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.07 CHF | -0.51% | -3.36% | +36.99% |
02:12pm | AlphaValue/Baader Europe Upgrades Sandoz Group to Add, Lifts PT | MT |
Nov. 27 | Glenmark Pharmaceuticals' US Arm Launches Travoprost Ophthalmic Solution | MT |
Capitalization | 18.4B 17.53B 16.44B 14.58B 26.2B 1,561B 28.95B 202B 74.75B 643B 69.14B 67.59B 2,828B | P/E ratio 2024 * |
28x | P/E ratio 2025 * | 19.1x |
---|---|---|---|---|---|
Enterprise value | 21.82B 20.79B 19.5B 17.29B 31.07B 1,851B 34.34B 240B 88.66B 763B 82B 80.17B 3,354B | EV / Sales 2024 * |
2.09x | EV / Sales 2025 * | 1.95x |
Free-Float |
-
| Yield 2024 * |
1.48% | Yield 2025 * | 1.93% |
Last Transcript: Sandoz Group AG
1 day | -0.36% | ||
1 week | -3.36% | ||
Current month | -7.65% | ||
1 month | -8.11% | ||
3 months | +5.25% | ||
6 months | +15.20% | ||
Current year | +36.99% |
Director | Title | Age | Since |
---|---|---|---|
Richard Saynor
CEO | Chief Executive Officer | 57 | 2022-01-16 |
Director of Finance/CFO | 56 | 2024-06-30 | |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | - |
Manager | Title | Age | Since |
---|---|---|---|
Karen Hübscher
BRD | Director/Board Member | 61 | 2023-07-31 |
Gilbert Ghostine
CHM | Chairman | 64 | 2023-02-28 |
Urs Riedener
BRD | Director/Board Member | 59 | 2023-07-31 |
Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
---|---|---|---|---|---|---|
-0.51% | -3.36% | +32.77% | - | 18.4B | ||
+0.44% | 0.00% | +48.89% | +138.19% | 51.04B | ||
-1.79% | -4.09% | +52.41% | +112.24% | 31.31B | ||
+0.13% | -3.40% | +20.74% | +61.91% | 13.75B | ||
+0.20% | +0.05% | +54.00% | +109.30% | 11.58B | ||
-.--% | +0.14% | - | - | 6.79B | ||
-.--% | -1.95% | - | - | 5.73B | ||
-1.87% | -4.52% | -35.47% | -38.81% | 5.29B | ||
-0.61% | +1.46% | +3.88% | +19.87% | 5.24B | ||
-1.10% | -1.72% | +90.40% | +188.73% | 5.1B | ||
Average | -0.50% | -1.39% | +33.45% | +84.49% | 15.42B | |
Weighted average by Cap. | -0.36% | -1.37% | +41.94% | +109.85% |
2024 * | 2025 * | |
---|---|---|
Net sales | 10.43B 9.94B 9.32B 8.26B 14.85B 885B 16.42B 115B 42.38B 365B 39.2B 38.32B 1,603B | 11.12B 10.59B 9.93B 8.81B 15.83B 943B 17.5B 122B 45.17B 389B 41.78B 40.84B 1,708B |
Net income | 629M 599M 562M 498M 895M 53.35B 990M 6.91B 2.56B 21.98B 2.36B 2.31B 96.65B | 947M 903M 846M 751M 1.35B 80.37B 1.49B 10.41B 3.85B 33.11B 3.56B 3.48B 146B |
Net Debt | 3.42B 3.26B 3.06B 2.71B 4.87B 290B 5.39B 37.61B 13.91B 120B 12.86B 12.58B 526B | 3.23B 3.08B 2.89B 2.56B 4.6B 274B 5.09B 35.51B 13.13B 113B 12.15B 11.88B 497B |
Date | Price | Change | Volume |
---|---|---|---|
24-12-13 | 37.07 CHF | -0.51% | 500,413 |
24-12-12 | 37.26 CHF | -0.59% | 634,648 |
24-12-11 | 37.48 CHF | -1.00% | 659,059 |
24-12-10 | 37.86 CHF | -0.18% | 617,151 |
24-12-09 | 37.93 CHF | -1.12% | 797,925 |
Delayed Quote Swiss Exchange, December 13, 2024 at 11:31 am EST
More quotesQuarterly revenue - Rate of surprise
- Stock Market
- Equities
- SDZ Stock